Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways

Francesca Bruzzese(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alfredo Budillon(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antonio Luciano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Biagio Pucci(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Monica Rocco(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Elena Di Gennaro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Chiara Ciardiello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandra Leone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Renato Franco(Istituto di Chimica Biomolecolare), Michele Caraglia(University of Campania "Luigi Vanvitelli"), Maria Rita Milone(Centro di Riferimento Oncologico), Maria Chianese(University of Trieste), Daniele Santini(Università Campus Bio-Medico), Claudio Arra(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cell Death and Disease
October 24, 2013
10.1038/cddis.2013.406
Cited by 57

Related Papers

<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
|JAMA Oncology|2018|418
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
|The Lancet Oncology|2020|322
Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain
|Journal of Clinical Oncology|2015|181
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
|Oncotarget|2016|166